Table 2. Summary of definitive potential therapeutic targets and drugs identified in the OncoKB database.
| Gene | Alteration | Pathway | OncoKB | |||
|---|---|---|---|---|---|---|
| Drugs | Level of evidence | Level-assoc. cancer types | ||||
| KRAS | WT | (6/19) | MAPK signalling | Regorafenib, panitumumab, cetuximab | 1 | Colorectal cancer |
| G12C | (1/19) | MAPK signalling | AMG-510 | 3A | Non-small cell lung cancer | |
| G12V/G12D/G13D/Q61H | (11/19) | MAPK signalling | Cobimetinib, binimetinib, trametinib | 4 | All solid tumours | |
| Oncogenic mutations | (12/19) | MAPK signalling | Panitumumab, cetuximab | R1 | Colorectal cancer | |
| PIK3CA | H1074R / E545K | (2/19) | PIK3-AKT-mTOR signalling | Fulvestrant+alpelisib | 1 | Breast cancer |
| AKT1 | E12K | (1/19) | PIK3-AKT-mTOR signalling | AZD5363 | 3A | Breast cancer, endometrial cancer, ovarian cancer |
| ATM | R3008H | (1/19) | Homologous recombination | Olaparib | 1 | Prostate cancer |
| Elevated tumour mutational burden | (5/19) | Immune checkpoint | Ipilimumab+nivolumab | 1 | Colorectal cancer | |
| Pembrolizumab | 1 | All solid tumours | ||||
OncoKB levels of evidence are defined as; level 1: FDA-approved, level 2: standard care, level 3A: clinical evidence, level 4: biological evidence and R1: resistance.
AKT, protein kinase B; FDA, Food and Drug Administration; MAPK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycin; PIK3, phosphoinositide 3-kinases; SNV, single nucleotide variant; WT, wild type.